SBIR/STTR Research Award

Peptide Based Therapy for Lung Fibrosis

Award identifier dead27cc6e64ce8cde158928e55ecdde8ecceab048bbb0297749ebc2dfdcd70fAwarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$1,492,847

Program and phase

STTR · Phase II

Award year

2016

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
Novici Biotech LLC
Proposal award date
2016-08-15
Contract end date
2019-05-31
UEI
MQ8XBWAV5826
Solicitation number
PA14-072
Topic code
NHLBI

Research abstract

DESCRIPTION provided by applicant Fibroproliferative illnesses leading to organ fibrosis and failure are responsible for approximately of deaths in developed countries whether idiopathic triggered by environmental factors infections or genetics organ fibrosis results in significant morbidity and mortality Organ fibrosis is responsible for health care costs exceeding $ billion year It is estimated that the number of deaths due to fibrosis is double the number of deaths due to cancer and that organ fibrosis results in significant physical emotional and financial burdens Specifically lung fibrosis can be idiopathic associated with connective tissue diseases or triggered by environmental and occupational exposures such as radiotherapy There are currently no effective therapies to treat existing lung fibrosis and the only option for patients is organ transplantation We have identified a peptide derived from endostatin now called Endopep which exerts anti fibrotic effects in vitro ex vivo and in vivo in pre clinical models of lung fibrosis Endopep was effective whether administered concomitantly with the fibrotic trigger or days after the trigger and appears to reverse fibrosis an effect not seen wit other drugs being evaluated for these illnesses We propose to produce recombinant Endopep by transient expression in whole plants and test the efficacy of the plant made product in our in vitro ex vivo and in vivo pre clinical models of fibrosis We also propose to conduct pharmacokinetic pharmacodynamic biodistribution and early toxicity studies in preparation for an IND application We have assembled a unique team with the expertise to express the peptide in plants conduct the pre clinical testing and complete the early PK PD biodistribution and toxicity studies in order to translate our findings to the clinic PUBLIC HEALTH RELEVANCE Pulmonary fibrosis is a terminal complication of diseases such as idiopathic pulmonary fibrosis IPF and systemic sclerosis SSc We have identified a novel peptide with anti fibrotic activity that is effective at blocking and reversing lung fibrosis We propose to manufacture the peptide in plants test the plant made product for efficacy in our pre clinical models and conduct pharmacokinetic biodistribution and early toxicity studies in preparation for IND application filing

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Awards with the same topic code

Verified by an exact topic code match. This is not a text-similarity match.

Research funding history

2 SBIR/STTR records share this UEI (2015–2016). Reported award amounts total $1,692,846. Reported amounts are not federal obligations.

Phases: Phase II, Phase I

Agencies: Department of Health and Human Services

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.